Optimal sampling time-point for cyclosporin A concentration monitoring in heart transplant recipients

about

Optimal sampling time-point for cyclosporin A concentration monitoring in heart transplant recipients

Item

http://www.wikidata.org/entity/Q58552338

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в листопаді 2018

@uk

name

Optimal sampling time-point fo ...... in heart transplant recipients

@en

Optimal sampling time-point fo ...... in heart transplant recipients

@nl

type

Item

label

Optimal sampling time-point fo ...... in heart transplant recipients

@en

Optimal sampling time-point fo ...... in heart transplant recipients

@nl

prefLabel

Optimal sampling time-point fo ...... in heart transplant recipients

@en

Optimal sampling time-point fo ...... in heart transplant recipients

@nl

P1476

Optimal sampling time-point fo ...... in heart transplant recipients

@en

P2093

Chunlei Xu

http://www.w3.org/2001/XMLSchema#string

Wei Han

http://www.w3.org/2001/XMLSchema#string

Wen Zeng

http://www.w3.org/2001/XMLSchema#string

Xu Meng

http://www.w3.org/2001/XMLSchema#string

Yan Li

http://www.w3.org/2001/XMLSchema#string

Yixin Jia

http://www.w3.org/2001/XMLSchema#string

Yuqing Jiao

http://www.w3.org/2001/XMLSchema#string

P2860

OPTN/SRTR 2011 Annual Data Report: heart.

Best single time point correlations with AUC for cyclosporine and tacrolimus in HIV-infected kidney and liver transplant recipients.

C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation.

Two-hour cyclosporine concentration determination: an appropriate tool to monitor neoral therapy?

Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I

Cyclosporine in thoracic organ transplantation.

Therapeutic drug monitoring of cyclosporine.

History of C2 monitoring in heart and liver transplant patients treated with cyclosporine microemulsion.

Cyclosporin therapeutic drug monitoring--an established service revisited.

Incidence of cancer after immunosuppressive treatment for heart transplantation.

P304

4265-4270

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/ETM.2018.6711

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30402164

http://www.w3.org/2001/XMLSchema#string

P921

cancer research

P932

6200973

http://www.w3.org/2001/XMLSchema#string